智通财经APP讯，满贯集团(03390)发布公告，于2025年4月29日，本公司与认购人Jacobson Group Treasury Limited，订立认购协议，本公司已有条件同意配发及发行，及认购人已有条件同意认购9400万 股认购股份，认购价为每股认购股份0.5港元。 根据认购事项将予配发及发行的9400万股认购股份总数，占于本公告日期本公司已发行股本的11.75%; 及透过发行认购股份扩大的本公司已发行股本约10.51%(假设自本公告日期起直至完成本公司已发行股 本并无变动，因认购事项产生者除外)。认购股份须受自完成日期起计6个月的禁售期所规限。 认购事项所得款项总额合共将为4700万港元，而认购事项所得款项净额(经扣除开支后)估计将合共约为 4670万港元。认购事项的全部所得款项净额拟用作投资于其核心业务以促进增长及扩展，改善其供应链 及物流业务以及一般营运资金。 董事会已通过一项批准认购事项的决议案。本公司认为，认购事项可增强本集团的财务状况，并为本集 团提供营运资金以应对任何未来发展及责任。本公司了解到，认购人拟长期持有于本公司的权益。雅各 臣科研制药集团为领先制药公司，凭藉在开发、生产及分销 ...

资料显示，满贯集团是香港大健康品牌全渠道营销管理商，专门为中成药、保健、皮肤护理、个人护理 及其他健康护理产品提供全渠道品牌代理、推广营销、管理及分销销售的一站式服务，在香港、澳门、 及东南亚等地覆盖接近十万个线上及线下销售点，销售超过300个本地及海外品牌，并积极开拓优质自 有品牌以及合作品牌产品，提供超过2000项产品。 值得一提的是，年报显示，2024年，满贯集团实现收入8.76亿港元，同比下降26.9%；实现股东应占溢 利324万港元，同比减少98.9%。 在股价暴跌后，有投资者对2024年的业绩提出了一些质疑。 4月17日，满贯集团（03390.HK）一度飙涨逾130%，涨幅也一度位列全市第一。 不过，在4月16日，满贯集团遭遇了瀑布式;闪崩下跌，市值直接跌去逾90%，已不足5亿港元。因此， 虽然4月17日股价出现大幅回升，但两日连起来看，股价的整体跌幅依然巨大，并直接放量跌成了仙 股;。 而满贯集团之所以在4月16日出现暴跌，其中一个原因是遭遇了强平。 4月16日晚间，满贯集团就股价与成交量异动发布公告称，公司主席兼控股股东王嘉俊最终控制的 Tycoon Empire所持1.29亿股普通股，已于4 ...

4月17日，截至港股收盘，恒生指数上涨1.61%，报21395.14点。满贯集团（03390.HK）收报0.53港元/ 股，上涨76.67%，成交量3.63亿股，成交额1.79亿港元，振幅106.67%。 最近一个月来，满贯集团累计跌幅92.19%，今年来累计跌幅91.38%，跑输恒生指数4.97%的涨幅。 财务数据显示，截至2024年12月31日，满贯集团实现营业总收入8.11亿元，同比减少26.91%；归母净利 润300.04万元，同比减少98.91%；毛利率26.56%，资产负债率51.37%。 （以上内容为金融界基于公开消息，由程序或算法智能生成，不作为投资建议或交易依据。） 本文源自：金融界 作者：行情君 行业估值方面，药品及生物科技行业市盈率（TTM）平均值为5.89倍，行业中值4.7倍。满贯集团市盈 率74.07倍，行业排名第73位；其他精优药业（00858.HK）为0.63倍、金斯瑞生物科技（01548.HK）为 0.98倍、百信国际（00574.HK）为1.49倍、东瑞制药（02348.HK）为2.78倍、帝王国际投资 （00928.HK）为4.43倍。 资料显示，满贯集团控股有限公司一直致 ...

港股满贯集团午后涨幅扩大至90%，成交超1亿港元，该股昨日大跌90%。 ...

港股满贯集团(03390.HK)午后涨幅扩大至90%，成交超1亿港元。该股昨日大跌90%，董事会主席兼控 股股东王嘉俊因股份成交价大幅下跌而出售1.29亿股。 ...

经就公司作出于当时情况下属合理的查询后，董事会确认，除上文所披露者外，董事会并不知悉导致有 关价格及成交量变动的任何原因，或为避免公司证券出现虚假市场而须予公布的任何资料，或根据证券 及期货条例第XIVA部须予披露的任何内幕消息。 此外，公司已向联交所申请于2025年4月17日上午九时正起恢复股份买卖。 满贯集团(03390)发布公告，公司董事会已注意到，于2025年4月16日，公司股份的股价下跌，成交量反 而上升。 经向董事作出适当查询后，公司获悉，由公司执行董事、董事会主席兼控股股东王嘉俊先生最终控制的 Tycoon Empire Investment Limited(Tycoon Empire)持有的1.29亿股公司普通股，已于2025年4月16日由 Tycoon Empire的股票经纪因股份于联交所成交价大幅下跌而出售(强制出售)。除所披露者外，董事并不 知悉股份价格出现上述异常下跌的原因。 紧随完成强制出售后及于本公告日期，王嘉俊先生及Tycoon Empire截至本公告日期持有的股份数目合 共为3.02亿股股份，相当于公司已发行股本的37.75%。公司亦已向公司若干其他股东作出查询，即华润 医药集 ...

Financial Performance - Total revenue for the fiscal year 2024 was HKD 876.0 million, a decrease of 26.9% compared to HKD 1,198.6 million in 2023[5] - The company's net profit attributable to equity holders dropped by 98.9% to HKD 3.2 million, with a profit margin of 0.4% compared to 24.8% in the previous year[5] - EBITDA for the fiscal year 2024 was HKD 41.9 million, down 88.4% from HKD 360.8 million in 2023, resulting in an EBITDA margin of 4.8%[5] - Adjusted net profit for the fiscal year was HKD 46.4 million, a decrease of 59.5% from HKD 114.8 million in 2023[5] - The group's gross profit decreased by 27.5% to HKD 232.7 million for the fiscal year, with a gross margin decline of 0.2 percentage points to 26.6% due to rising commodity costs[31] - Other income and net other gains for the fiscal year were HKD 4.8 million, a significant drop from HKD 209.0 million in the previous fiscal year, primarily due to the one-time gain from the sale of 51% equity in CWA[32] - Profit attributable to equity holders of the company was HKD 6.0 million, down from HKD 297.3 million in the previous fiscal year, mainly due to the absence of one-time gains from the sale of CWA and increased share-based payment expenses[33] Revenue Breakdown - Retail revenue increased by 63.4% year-on-year to HKD 176.4 million, while distribution sales in Hong Kong grew by 3.3% to HKD 533.0 million[7] - Southeast Asia distribution sales reached HKD 77.3 million, a significant increase of 63.5% year-on-year, with Singapore contributing HKD 65.6 million, up 56.9%[8] - Revenue from Hong Kong increased by 13.7% to HKD 709.4 million in fiscal year 2024, compared to HKD 623.7 million in fiscal year 2023, despite a slight growth in distribution business[30] - Revenue from Singapore, Malaysia, and other regions surged by 59.8% to HKD 77.3 million in fiscal year 2024, up from HKD 48.3 million in fiscal year 2023[30] - Macau's revenue decreased by 20.7% to HKD 89.3 million in fiscal year 2024, down from HKD 112.7 million in fiscal year 2023, attributed to changes in consumer spending patterns[30] Strategic Initiatives - The company plans to maintain market share in Hong Kong and Macau while controlling costs and enhancing profit margins through strategic partnerships and product diversification[9] - The company aims to develop proprietary and collaborative brands to enhance profitability and meet market trends[9] - The company anticipates significant growth in distribution sales in Thailand, with revenue expected to multiply by the end of the fiscal year 2025[10] - The company plans to leverage the updated free trade agreement with ASEAN, which expanded covered product categories from over 200 to nearly 600, to enhance competitiveness in Southeast Asia[14] - The company aims to continue expanding its market share and product offerings in the Asia-Pacific region, focusing on health and wellness products[10] Dividend Policy - The board decided not to declare a final dividend for the fiscal year due to the uncertain operating environment[7] - The board has decided not to declare any final dividend for the 2024 financial year, compared to a dividend of HKD 0.035 per share for the 2023 financial year[65] - The board will continue to review the dividend policy, which has been in effect since April 15, 2020, allowing for the declaration of interim or special dividends[91] - The company has adopted a dividend policy that requires consideration of various factors, including financial performance and cash flow[95] Corporate Governance - The board consists of eight members, including one executive director, four non-executive directors, and three independent non-executive directors[193] - The board held five meetings during the fiscal year to review financial and operational performance and discuss future strategies[196] - The company has adhered to all corporate governance code provisions during the fiscal year, except for deviation from provision C.2.1[191] - The company emphasizes high ethical standards and believes that acting with integrity and transparency will maximize long-term shareholder returns[188] - The company has established a corporate governance committee responsible for formulating and reviewing governance policies and practices[190] Shareholder Information - The company has a significant shareholder, Tycoon Empire, holding 432,616,326 shares, representing 54.08% of the total shares[133] - Major shareholder Wei Siqi also holds 432,616,326 shares, equivalent to 54.08%[137] - China Resources Pharmaceutical Retail holds 151,895,000 shares, accounting for 18.99% of the total shares[137] - Jacobson Group Treasury Limited owns 56,590,000 shares, which is 7.07% of the total shares[137] - The company has not entered into any significant contracts with its controlling shareholders during the fiscal year[132] Employee Information - The number of employees increased to 260 as of December 31, 2024, compared to 130 in the previous year[64] - Total employee costs for the financial year amounted to approximately HKD 89 million, up from HKD 65.9 million in the previous financial year[64] Risk Management - The group closely monitors foreign exchange risks and may consider hedging significant foreign exchange risks when necessary[41] - The company faces risks related to consumer preferences and spending patterns, which could significantly impact its business and financial performance[67] Related Party Transactions - The total amount of related party transactions disclosed did not exceed the set annual cap, except for the previously mentioned excess[128] - The company has not engaged in any other related party transactions during the fiscal year, aside from those disclosed[125] Acquisitions and Investments - The group completed the acquisition of 12% equity in 康寧行 for a total consideration of HKD 9.1 million on May 31, 2023, increasing ownership to 61%[44] - On March 28, 2024, the group further acquired an additional 9% equity in 康寧行 for HKD 6.8 million, raising total ownership to 70%[45] - The company plans to acquire the remaining 51% of CWA Group for a cash settlement of HKD 106.0 million due to a triggered put option[177] Compliance and Legal - The company has established compliance and risk management policies, ensuring adherence to significant legal and regulatory requirements[173] - The company has committed to environmental protection and has complied with all relevant environmental laws during the fiscal year[172]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 Tycoon Group Holdings Limited 滿貫集團控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：3390） 截至2024年12月31日止年度的年度業績公告 財務摘要 滿貫集團控股有限公司（「本公司」）董事（「董事」）會（「董事會」）欣然宣佈本公司及其附屬公司（統稱「本 集團」或「滿貫集團」）截至2024年12月31日止年度的經審核綜合年度業績，連同2023年同期的比較數 字： 1 • 本集團截至2024年12月31日止年度（「本財政年度」或「2024年財政年度」）的收入為876.0百萬港 元，較截至2023年12月31日止年度（「2023年財政年度」）的1,198.6百萬港元減少26.9%。 • 本集團2024年財政年度的淨溢利為6.0百萬港元，較2023年財政年度的297.3百萬港元減少 98.0%。 • 本集團2024年財政年度的EBITDA （非香港財務報告準則計量 ...

TYL 滿貫集團控股有限公司 Tycoon Group Holdings Limited (於閲曼群島註冊成立的有限公司) 股份代號：3390 00 2024 目錄 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |----------------------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 頁碼 | | 公司資料 | | | | | | | | | 2 | | | | | | | | | | | | | 財務摘要 | | | | | | | | | 3 | | 管理層討論及分析 | | | | | | | | | 4 | | 企業管治及其他資料 | | | | | | | | | 18 | | | | | | | | | | | | | 中期簡明綜合損益及其他全面收益表 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 Tycoon Group Holdings Limited 滿貫集團控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：3390） 截至2024年6月30日止六個月的中期業績公告 | --- | --- | |-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | 財務摘要 | | • | 本集團截至 2024 年 6 月 30 日止六個月（「 回顧期內 」或「 2024 年上半年 」）的收入為 435.0 ...